# Baxter to acquire Claris Injectables for $625 million

Baxter International entered a definitive agreement to acquire Claris Injectables Limited, a subsidiary of Claris Lifesciences, for approximately $625 million. The deal is expected to close in the second half of 2017.

- Type: Acquisition
- Announced: 2016-12-15
- Where: Ahmedabad, India, India
- Value: $625.0M
- Status: announced
- Products: generic injectable medicines, anesthesia, analgesics, renal drugs, anti-infectives, critical care medicines
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Baxter International](https://endata.com/companies/20761.md) (acquirer)
- [Claris Injectables Limited](https://endata.com/companies/20762.md) (target)
- [Claris Lifesciences Limited](https://endata.com/companies/20763.md) (partner)
- [Claris Lifesciences Limited](https://endata.com/companies/20763.md) (target)

## Sources

- [baxter.ca](https://www.baxter.ca/baxter-newsroom/baxter-expand-portfolio-essential-generic-injectable-medicines-acquisition-claris), 2016-12-15: "Sterile medication production is a core competency for Baxter, which manufactures a broad range of essential generic injectable medications."
- [timesofindia.indiatimes.com](https://timesofindia.indiatimes.com/business/india-business/baxter-buys-claris-arm-for-rs-4-2k-cr/articleshow/56009360.cms), 2016-12-15: "The acquisition of Claris Injectables will allow Baxter to make an even greater impact for patients and healthcare providers while creating new opportunities for Baxter to accelerate near-term and long-term performance."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.